Abrocitinib ni umunwa, molekile ntoya, Janus kinase (JAK) 1 inhibitor mugutezimbere kuvura abantu bakuru ningimbi bafite dermatite itagereranywa kandi ikabije.

Abrocitinib iri gukurikiranwa mu igeragezwa ry’amavuriro NCT03796676 (JAK1 Inhibitor hamwe nubuvuzi bwa Topical Therapy ku rubyiruko rufite Dermatite ya Atopic).

Muri iki gihe Abrocitinib irimo gutegurwa na Pfizer yo kuvura dermatite ya atopic (eczema).Numunwa wiperereza rimwe-buri munsi Janus kinase 1 (JAK1) inhibitor.

Indwara ya Atopic dermatitis (AD) ni indwara igoye, idakira, yanduza uruhu irangwa na pruritike, kwandura cyane, ndetse no gukomeretsa eczematous yibasira abana bagera kuri 25% na 2% kugeza 3% byabantu bakuru ku isi.Abrocitinib ni inhibitori ya Janus kinase-1 (JAK1) enzyme ibuza inzira yo gutwika.Kubwibyo, twari tugamije gusuzuma imikorere n'umutekano bya abrocitinib kuri AD igereranije-ikomeye.

Abrocitinib muri dose 100 mg cyangwa 200 mg ni imiti ikora neza, yihanganira neza, kandi itanga ikizere cyo kuvura abarwayi bafite dermatite ya atopic itagabanije cyane.Nyamara, isesengura ryashimangiye imikorere ya abrocitinib 200 mg hejuru ya mg 100, ariko ingaruka mbi nko kugira isesemi no kubabara umutwe birashoboka cyane hamwe na mg 200.